Relapsed Acute Myeloid Leukemia Drug Market
Global Relapsed Acute Myeloid Leukemia Drug Market Size, Share, and Trend Analysis Report, By Type (aNK Program, AT-9283, BI-836858, Binimetinib, BL-8040, and Others) and By Application (Clinics, Hospitals, and Others) for the Forecast (2022-2028) Update Available - Forecast 2024-2030
The global relapsed acute myeloid leukemia market is anticipated to grow at a significant CAGR of 7.2 % during the forecast period (2022-2028). The new launches of drugs and medicines to treat patients suffering from acute myeloid leukemia are propelling the growth of the market. For instance, in May 2019, Tibsovo (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test. Tibsovo is an oral, targeted inhibitor of the IDH1 enzyme, and is the first and only FDA-approved therapy for patients with AML and an IDH1 mutation which is present in approximately 6-10% of AML patients. Tibsovo works by decreasing the body’s abnormal production of the oncometabolite 2-hydroxyglutarate (2-HG) which will eventually restore the ability of cancerous cells to differentiate.
Impact of COVID-19 Pandemic on Global Relapsed Acute Myeloid Leukemia Drug Market
The COVID-19 pandemic had impacted the global relapsed acute myeloid leukemia industry significantly owning to the lockdown in most of the nations to control the spread of the virus. The COVID-19 pandemic poses several challenges to the management of patients with leukemia. The biology of each leukemia and its corresponding treatment with conventional intensive chemotherapy, with or without targeted therapies (venetoclax, FLT3 inhibitors, IDH1/2 inhibitors, Bruton’s tyrosine kinase inhibitors), introduce additional layers of complexity during COVID-19 high-risk periods, which had restrained the growth of the market over the forecast.
Segmental Outlook
The global relapsed acute myeloid leukemia market is segmented based on type and application. Based on the type, the market is segmented into aNK program, AT-9283, BI-836858, Binimetinib, BL-8040, and others. Based on the application, the market is sub-segmented into Clinic, Hospital, and others. Based on type, Binimetinib is expected to drive growth in the relapsed acute myeloid leukemia market. Binimetinib is used to treat a type of skin cancer (melanoma). Binimetinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.
Global Relapsed Acute Myeloid Leukemia Drug Market Share by Application, 2021 (%)
The Hospital is Expected to Holds the Prominent Share in the Global Relapsed Acute Myeloid Leukemia Drug Market
The Hospital segment is expected to Holds the prominent share during the forecast period in the global relapsed acute myeloid leukemia market in the application segment. This is due to the fact that hospitals have distinct departments and services dedicated to cancer treatments, including chemotherapy. These centers provide best practices for AML, such as pharmacological therapy, blood transfusions, stem cell transplants, and so on. Furthermore, it might arise months to years following therapy. Additionally, practically every patient is at risk of recurrence, with the majority of relapses happening within two to three years of starting therapy. As a result, the increased rate of relapsed AML is driving market expansion.
Regional Outlooks
The global relapsed acute myeloid leukemia market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). Among all regions, Europe is expected to hold a significant share in the relapsed acute myeloid leukemia market. Due to increasing awareness among people about various cancer types across the region including AML caused by exposure to chemical substances such as benzene which can lead to germinal cells toward leukemic transformation, is expected to drive the growth of the market.
Global Relapsed Acute Myeloid Leukemia Drug Market Growth, by Region 2022-2028
The North America Region is Expected to Hold Considerable Share in the Global Relapsed Acute Myeloid Leukemia Drug Market
Among all regions, the North America region is expected to hold a considerable share in the global relapsed acute myeloid leukemia drug market over the forecast. This is expected on account of factors such as technological development in this region driven by increasing healthcare expenditure that stimulates companies into finding new avenues of treatment for diseases with high unmet needs.
Market Players Outlook
The major companies serving the global relapsed acute myeloid leukemia market include among the top participants in the market are AbbVie, Amgen, and Novartis International AG. To remain competitive in the market, industry players are using different tactics such as mergers and acquisitions, regional expansion, partnerships and collaborations, and new product launches, which contribute considerably to market growth. For example, Gilead Sciences, Corp. announced in March 2020 that it will purchase Forty-Seven, for $4.9 billion. Gilead's immuno-oncology research and development portfolio was bolstered by the purchase. Through the addition of Forty Seven’s investigational lead product candidate, magrolimab, the acquisition will strengthen Gilead’s immuno-oncology research and development portfolio. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers for which new, transformative medicines are urgently needed, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and diffuse large B-cell lymphoma (DLBCL).
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global relapsed acute myeloid leukemia market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on the Global Relapsed Acute Myeloid Leukemia Medication Market
- Recovery Scenario of Global Relapsed Acute Myeloid Leukemia Medication Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. 4SC AG
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. AbbVie
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Actinium Pharmaceuticals
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Agios Pharmaceuticals
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Amgen
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of COVID-19 on Key Players
4. Market Segmentation
4.1. Global Relapsed Acute Myeloid Leukemia Medication Market by Type
4.1.1. aNK programme
4.1.2. AT-9283
4.1.3. BI-836858
4.1.4. Binimetinib
4.1.5. BL-8040
4.1.6. Others
4.2. Global Relapsed Acute Myeloid Leukemia Medication Market by Application
4.2.1. Hospital
4.2.2. Clinic
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. US
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Arog Pharmaceuticals.
6.2. Array BioPharma
6.3. Astellas Pharma.
6.4. Astex Pharmaceuticals.
6.5. AstraZeneca Plc
6.6. AVEO Pharmaceuticals.
6.7. BioLineRx, Ltd.
6.8. Boehringer Ingelheim GmbH
6.9. Boston Biomedical
6.10. Bristol-Myers Squibb Co.
6.11. Calithera Biosciences
6.12. Celgene Corp.
6.13. Cornerstone Pharmaceuticals
1. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ANK PROGRAMME RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL AT-9283 RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL BI-836858 RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL BINIMETINIB RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL BL-8040 RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL OTHER RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
9. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION FOR HOSPITALS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION FOR CLINICS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
13. NORTH AMERICAN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. NORTH AMERICAN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. NORTH AMERICAN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. EUROPEAN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. EUROPEAN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. EUROPEAN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. ASIA-PACIFIC RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. ASIA-PACIFIC RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. ASIA-PACIFIC RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
22. REST OF THE WORLD RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
23. REST OF THE WORLD RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
24. REST OF THE WORLD RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET, 2022-2028 (%)
4. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ANK PROGRAMME RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL AT-9283 RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL BI-836858 RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL BINIMETINIB RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL BL-8040 RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL OTHER RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
12. GLOBAL HOSPITAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL CLINIC RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL OTHER RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. US RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
17. CANADA RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
18. UK RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
19. FRANCE RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
20. GERMANY RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
21. ITALY RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
22. SPAIN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF EUROPE RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
24. INDIA RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
25. CHINA RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
26. JAPAN RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
27. SOUTH KOREA RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF ASIA-PACIFIC RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD RELAPSED ACUTE MYELOID LEUKAEMIA MEDICATION MARKET SIZE, 2021-2028 ($ MILLION)
